Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Container Clear all
Active, not recruiting Not applicable Interventional Results available

Proton Beam Therapy in the Treatment of Esophageal Cancer

NCT03482791
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Proton beam therapy, Patient-Reported Outcome Measures
Radiation · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Completed No phase listed Observational

Grappler Interference Screw Post-Market Collection of Patient Reported Outcome Measures

NCT05190874
View directory record Official record
Conditions
Ankle Injuries, Syndesmotic Injuries, Ankle Inversion Sprain, Deltoid Ankle Sprain, Achilles Tendon Rupture, Flexor Hallucis Longus on the Left, Flexor Hallucis Longus on the Right, Flexor Digitorum Longus on the Left, Flexor Digitorum Longus on the Right, Ankle Sprains
Interventions
Grappler Interference Screw System
Device
Lead sponsor
Paragon 28
Industry
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Worthington, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Recruiting No phase listed Observational

Acute Subdural Hematoma

NCT07490197
View directory record Official record
Conditions
Trauma
Interventions
Medical/Phenotype Data Collection Procedures & Data to be Collected
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Active, not recruiting Not applicable Interventional

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

NCT04236882
View directory record Official record
Conditions
Behavioral Disorder, Endocrine System Disorder
Interventions
Focus Group, Health Education, Internet-Based Intervention, Interview, Questionnaire Administration
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

NCT04729959
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions
Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
110
States / cities
Anaheim, California • Bellflower, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

NCT05487846
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Patient Navigation, Genetic Counseling, Survey Administration, Best Practice
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Completed No phase listed Observational

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1

NCT02974335
View directory record Official record
Conditions
Addiction
Interventions
Interviews with Stakeholders
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action

NCT03607617
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
SDH Tool
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep for Inpatients: Empowering Staff to Act

NCT02025959
View directory record Official record
Conditions
Sleep Disorders, Sleep
Interventions
Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 3, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Communicating Multiple Disease Risks: A Translation of Risk Prediction Science

NCT03255291
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risk Assessment App, Audio Recording - Sleep, Surveys, Audio Recording - Exercise, Text message reminders, Text Message Survey
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years to 64 Years
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 3, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation of the VIDAS TB-IGRA Assay.

NCT04048018
View directory record Official record
Conditions
Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
Interventions
Blood draw and IGRA test
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
2 Years and older
Enrollment
2,401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 3, 2026, 6:42 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Stem Cell Collection for Adult Volunteers

NCT00033774
View directory record Official record
Conditions
Sickle Cell
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Terminated No phase listed Observational

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

NCT05437679
View directory record Official record
Conditions
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
Blood collection
Other
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 3, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03129061
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Withdrawn Not applicable Interventional

OsseoFit™ Prospective Data Collection

NCT00708474
View directory record Official record
Conditions
Bone Graft, Knee
Interventions
OsseoFit™ Porous Tissue Matrix™
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Warsaw, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 3, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

NCT07407920
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Hormone Therapy, Pembrolizumab, Pertuzumab, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Active, not recruiting Not applicable Interventional

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer

NCT05075759
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Survey Administration, Interview
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 54 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 3, 2026, 6:42 AM EDT
Not listed No phase listed Observational

A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits

NCT04668846
View directory record Official record
Conditions
Dermatologic Diseases
Interventions
non-invasive sample collection of skin tissue
Other
Lead sponsor
DermTech
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Timeline
2020 – 2023
U.S. locations
2
States / cities
Denver, Colorado • Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Not listed No phase listed Observational

Diagnosis of Alzheimer's Disease Using Event Related Potentials

NCT02957227
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
No intervention is part of this study but patients use an EEG device during observational data collection.
Device
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Completed No phase listed Observational

Smoking Status and Body Image in Oral Cancer Patients

NCT00412490
View directory record Official record
Conditions
Oral Cavity Cancer
Interventions
Questionnaire, Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 3, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Biobehavioral Effects of Emotional Expression in Cancer

NCT00505310
View directory record Official record
Conditions
Kidney Cancer
Interventions
Writing, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 3, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Blood sampling
Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 3, 2026, 6:42 AM EDT